NMRA
Neumora Therapeutics, Inc.
Biotechnology · Healthcare · United States
0.37
close · 2026-10-30
value
1
cheaper than peers1
quality
8
stronger fundamentals8
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.54× | 67 |
| earnings yield, 3 years ago | -234.6% | 18 |
| cash flow yield, 3 years ago | -167.3% | 6 |
| cash flow yield, 2 years ago | -236.8% | 5 |
| earnings yield, 1 year ago | -416.7% | 4 |
| cash flow yield, 1 year ago | -265.1% | 4 |
| earnings yield, latest year | -394.9% | 2 |
| cash flow yield, latest year | -299.2% | 1 |
| earnings yield, 2 years ago | -988.6% | 0 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| return on equity | -187.1% | 14 |
| debt to equity | 119.6% | 8 |
3 of 4 measures available
Facts
| market cap | $69M |
| free cash flow | -$99.4M |
| employees | 63 |
| first trade | 2023-09-14 |
| next earnings | 2026-08-14 |
| fundamentals updated | 2026-08-21 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.45 | -1.53 | -3.63 | -0.86 |
| free cash flow | -$206.4M | -$182.9M | -$163.4M | -$115.4M |
| net income | -$236.9M | -$243.8M | -$235.9M | -$130.9M |
| revenue | $0 | $0 | $0 | $0 |